title: Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation.
abstract: Breast cancer carrying BRCA mutation may be highly sensitive to DNA-damaging agents. We hypothesized a better outcome for BRCA-mutated (BRCA(mut)) metastatic breast cancer (MBC) patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation (HDC AHSCT) versus unaffected BRCA (BRCA wild type; (BRCA(wt))) or patients without documented BRCA mutation (BRCA untested (BRCA(ut))). All female patients treated for MBC with AHSCT at Institut Paoli-Calmettes between 2003 and 2012 were included. BRCA(mut) and BRCA(wt) patients were identified from our institutional genetic database. Overall survival (OS) was the primary end point. A total of 235 patients were included. In all, 15 patients were BRCA(mut), 62 BRCA(wt) and 149 BRCA(ut). In multivariate analyses, the BRCA(mut) status was an independent prognostic factor for OS (hazard ratio (HR): 3.08, 95% confidence interval (CI): 1.10-8.64, P=0.0326) and PFS (HR: 2.52, 95% CI :1.29-4.91, P=0.0069). In this large series of MBC receiving HDC AHSCT, we report a highly favorable survival outcome in the subset of patients with documented germline BRCA mutations.
authors.affiliation: Département d'Oncologie Médicale, Institut Paoli-Calmettes (IPC), Marseille, France.
authors.forename: L
authors.initials: L
authors.lastname: Boudin
authors.affiliation: Département d'Oncologie Médicale, Institut Paoli-Calmettes (IPC), Marseille, France.|Centre de Recherches en Cancérologie de Marseille (CRCM), Marseille, France.|Aix-Marseille Université, Marseille, France.
authors.forename: A
authors.initials: A
authors.lastname: Gonçalves
authors.affiliation: Département d'Oncologie Médicale, Institut Paoli-Calmettes (IPC), Marseille, France.|Centre de Recherches en Cancérologie de Marseille (CRCM), Marseille, France.
authors.forename: R
authors.identifier: 0000-0002-5821-682X
authors.initials: R
authors.lastname: Sabatier
authors.affiliation: Département d'Anticipation et de Suivi du Cancer, Institut Paoli-Calmettes, Marseille, France.
authors.forename: J
authors.initials: J
authors.lastname: Moretta
authors.affiliation: Biostatistiques, Département de la Recherche Clinique et de l'Innovation (DRCI), Institut Paoli-Calmettes, Marseille, France.
authors.forename: P
authors.initials: P
authors.lastname: Sfumato
authors.affiliation: Département d'Anticipation et de Suivi du Cancer, Institut Paoli-Calmettes, Marseille, France.
authors.forename: P
authors.initials: P
authors.lastname: Asseeva
authors.affiliation: Département d'Anticipation et de Suivi du Cancer, Institut Paoli-Calmettes, Marseille, France.
authors.forename: D
authors.initials: D
authors.lastname: Livon
authors.affiliation: Département d'Oncologie Médicale, Institut Paoli-Calmettes (IPC), Marseille, France.|Centre de Recherches en Cancérologie de Marseille (CRCM), Marseille, France.|Aix-Marseille Université, Marseille, France.
authors.forename: F
authors.initials: F
authors.lastname: Bertucci
authors.affiliation: Département d'Oncologie Médicale, Institut Paoli-Calmettes (IPC), Marseille, France.
authors.forename: J-M
authors.initials: JM
authors.lastname: Extra
authors.affiliation: Département d'Oncologie Médicale, Institut Paoli-Calmettes (IPC), Marseille, France.
authors.forename: C
authors.initials: C
authors.lastname: Tarpin
authors.affiliation: Centre de Recherches en Cancérologie de Marseille (CRCM), Marseille, France.|Aix-Marseille Université, Marseille, France.|Département de Chirurgie Oncologique, Institut Paoli-Calmettes, Marseille, France.
authors.forename: G
authors.initials: G
authors.lastname: Houvenaeghel
authors.affiliation: Centre de Recherches en Cancérologie de Marseille (CRCM), Marseille, France.|Aix-Marseille Université, Marseille, France.|Département de Chirurgie Oncologique, Institut Paoli-Calmettes, Marseille, France.
authors.forename: E
authors.initials: E
authors.lastname: Lambaudie
authors.affiliation: Département de Radiothérapie, Institut Paoli-Calmettes, Marseille, France.
authors.forename: A
authors.initials: A
authors.lastname: Tallet
authors.affiliation: Département de Radiothérapie, Institut Paoli-Calmettes, Marseille, France.
authors.forename: M
authors.initials: M
authors.lastname: Resbeut
authors.affiliation: Aix-Marseille Université, Marseille, France.|Département d'Anticipation et de Suivi du Cancer, Institut Paoli-Calmettes, Marseille, France.
authors.forename: H
authors.initials: H
authors.lastname: Sobol
authors.affiliation: Centre de Recherches en Cancérologie de Marseille (CRCM), Marseille, France.|Aix-Marseille Université, Marseille, France.|Biopathologie, Département de Biologie du Cancer Institut Paoli-Calmettes, Marseille, France.
authors.forename: E
authors.initials: E
authors.lastname: Charafe-Jauffret
authors.affiliation: Centre de Recherches en Cancérologie de Marseille (CRCM), Marseille, France.|Centre de Thérapie Cellulaire, Département de Biologie du Cancer, Institut Paoli-Calmettes, Marseille, France.|Centre d'Investigations Cliniques en Biothérapies, Marseille, France.
authors.forename: B
authors.initials: B
authors.lastname: Calmels
authors.affiliation: Centre de Thérapie Cellulaire, Département de Biologie du Cancer, Institut Paoli-Calmettes, Marseille, France.|Centre d'Investigations Cliniques en Biothérapies, Marseille, France.
authors.forename: C
authors.initials: C
authors.lastname: Lemarie
authors.affiliation: Biostatistiques, Département de la Recherche Clinique et de l'Innovation (DRCI), Institut Paoli-Calmettes, Marseille, France.
authors.forename: J-M
authors.initials: JM
authors.lastname: Boher
authors.affiliation: Département d'Oncologie Médicale, Institut Paoli-Calmettes (IPC), Marseille, France.|Centre de Recherches en Cancérologie de Marseille (CRCM), Marseille, France.|Aix-Marseille Université, Marseille, France.
authors.forename: P
authors.initials: P
authors.lastname: Viens
authors.affiliation: Centre de Recherches en Cancérologie de Marseille (CRCM), Marseille, France.|Aix-Marseille Université, Marseille, France.|Département d'Anticipation et de Suivi du Cancer, Institut Paoli-Calmettes, Marseille, France.
authors.forename: F
authors.initials: F
authors.lastname: Eisinger
authors.affiliation: Centre de Recherches en Cancérologie de Marseille (CRCM), Marseille, France.|Aix-Marseille Université, Marseille, France.|Biopathologie, Département de Biologie du Cancer Institut Paoli-Calmettes, Marseille, France.|Centre de Thérapie Cellulaire, Département de Biologie du Cancer, Institut Paoli-Calmettes, Marseille, France.
authors.forename: C
authors.identifier: 0000-0002-3755-4889
authors.initials: C
authors.lastname: Chabannon
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage; D019313:BRCA1 Protein / Q000235:genetics*; D024682:BRCA2 Protein / Q000235:genetics*; D001943:Breast Neoplasms / Q000235:genetics / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods / Q000401:mortality; D006801:Humans; D009154:Mutation; D009362:Neoplasm Metastasis; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D019313:BRCA1 Protein; C492913:BRCA1 protein, human; D024682:BRCA2 Protein; C551750:BRCA2 protein, human